Bioventus continues expanding orthobiologic therapies designed for musculoskeletal healing and recovery. Institutional portfolio adjustments bring renewed focus to the medical technology developer.
Medical technology firm Bioventus concluded its 2025 fiscal year with robust fourth-quarter performance, surpassing analyst ...
Bioventus develops musculoskeletal therapies including biologics and nerve stimulation systems. Discover company developments ...
Bioventus Inc. (NASDAQ:BVS) Q4 2025 Earnings Call Transcript March 5, 2026 Bioventus Inc. misses on earnings expectations. Reported EPS is $0.2141 EPS, expectations were $0.22. Operator: Good day, and ...
Detailed price information for Henry Schein Inc (HSIC-Q) from The Globe and Mail including charting and trades.
Bioventus (NASDAQ:BVS) executives told investors the company closed 2025 with what leadership described as a “solid quarter” and a “pivotal year,” highlighting stronger organic growth, higher ...
Q4 2025 earnings call recap: 2026 sales/EPS guidance, margin and cash flow gains, and growth bets on PNS/PRP—read insights now.
Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0%Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year periodNon-GAAP ...
Investing.com -- Shares of Bioventus (NASDAQ:BVS) climbed 7.58% to $9.11 in premarket trading on Thursday after the medical device maker reported fourth-quarter results that exceeded Wall Street ...
For fiscal 2026, Bioventus issued guidance of $600-610 million in revenue, with a midpoint of $605 million slightly above the analyst consensus of $604.2 million. The company expects adjusted EPS of ...
Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0%Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year periodNon-GAAP earn ...
(BVS) on Thursday reported fourth-quarter profit of $14.8 million. The Durham, North Carolina-based company said it had profit of 21 cents ...